Categories: Journal

Binaytara Foundation Announces Dr. Umang Swami as Editor-in-Chief of the International Journal of Cancer Care & Delivery (IJCCD)

Swami Envisions the IJCCD as a Leading Journal in Cancer Health Disparities

The Binaytara Foundation has named Dr. Umang Swami as the Editor-in-Chief of the International Journal of Cancer Care and Delivery. Dr. Swami is an Assistant Professor in the Department of Oncology at the Huntsman Cancer Institute at the University of Utah. He has been the reviewer and editor of multiple journals.

“My background of working in two vastly different health care setups (India and USA) gives me a unique insight into disparities across the globe. I aim to make IJCCD not only a journal disseminating recent medical advances but also focusing on disparities and treatment approaches focused on unique challenges in resource constrained countries and populations.”

Dr. Umang Swami

Dr. Swami will be responsible for the journal’s peer review process, academic quality, and providing leadership for the editorial board and its meetings. He will identify and invite leaders and experts in the field to publish their research, reviews, and opinions in the Journal. 

The International Journal of Cancer Care and Delivery (IJCCD) publishes original research, review articles, case reports, opinions/commentaries, letters to the editor, editorials, and special articles that “inform and educate clinicians and healthcare leaders about innovative, sustainable, scalable solutions to problems that create barriers to care. The journal encourages cancer care professionals around the world to share the unique approaches and processes they implement at their practice to overcome everyday barriers to care delivery.” Swami explained.

The Journal stands apart from others in its focus on addressing disparities in health care by providing the latest research and advancements in oncology and how it can be applied in resource constrained settings.

“My vision is to make IJCCD as a leading journal in cancer health disparities and go to journal for resource constrained situations while at the same time also focusing on recent advancements.” Dr. Swami said.

We are excited to see the impact that Dr. Swami has on the journal as he provides leadership and increases the impact of the research and information it presents.


The Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal.

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

7 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

7 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago